Literature DB >> 3691604

The efficacy of a transdermal formulation of clonidine in mild to moderate hypertension and its effects on the arterial and venous vasculature of the forearm.

A Achimastos1, X Girerd, A C Simon, I Pithois-Merli, J Levenson.   

Abstract

We have studied the efficacy of clonidine hydrochloride administered transdermally once a week for 9 to 15 weeks in 12 patients with mild to moderate hypertension. Clonidine reduced both supine and standing blood pressures on average, but only 8 subjects were responders, i.e. had a decrease in supine diastolic blood pressure to below 90 mm Hg or more than 10% from baseline. Supine heart rate was unchanged, but in the responders the orthostatic increase in heart rate was reduced by clonidine from baseline (p less than 0.05). Moreover, in all the patients the change in the orthostatic increase in heart rate was correlated with the change in supine diastolic pressure (p less than 0.05). Brachial artery blood flow, forearm arterial compliance, vascular resistance, and venous tone were not affected by clonidine. Thus, transdermal clonidine reduced blood pressure, probably by a baroreflex-mediated effect, but did not affect the vasculature of the forearm.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691604     DOI: 10.1007/bf00544552

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Hypertension in the elderly.

Authors:  J Rosenfeld
Journal:  Kidney Int       Date:  1983-03       Impact factor: 10.612

2.  The effects of clonidine and propranolol, separately and in combination, on blood pressure and plasma renin activity in essential hypertension.

Authors:  M A Weber; J I Drayer; J H Laragh
Journal:  J Clin Pharmacol       Date:  1978 May-Jun       Impact factor: 3.126

3.  Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.

Authors:  J E Shaw
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

4.  Transdermal administration of clonidine for treatment of high BP.

Authors:  M A Weber; J I Drayer; F G McMahon; R Hamburger; A R Shah; L N Kirk
Journal:  Arch Intern Med       Date:  1984-06

5.  Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm.

Authors:  A C Simon; J A Levenson; J D Bouthier; A Benetos; A Achimastos; M Fouchard; B C Maarek; M E Safar
Journal:  Am J Cardiol       Date:  1984-03-01       Impact factor: 2.778

6.  Large arteries in hypertension: acute effects of a new calcium entry blocker, nitrendipine.

Authors:  J Levenson; A C Simon; M E Safar; J Bouthier; B C Maarek
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

7.  Post-synaptic alpha-blockade and brachial artery compliance in essential hypertension.

Authors:  J Levenson; A C Simon; J D Bouthier; A Benetos; M E Safar
Journal:  J Hypertens       Date:  1984-02       Impact factor: 4.844

8.  Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension.

Authors:  A C Simon; J Levenson; J D Bouthier; M E Safar
Journal:  J Cardiovasc Pharmacol       Date:  1985 Sep-Oct       Impact factor: 3.105

9.  The use of transcutaneous clonidine hydrochloride in the patient with diabetes mellitus and mild hypertension.

Authors:  J D Wallin; N K Krane; S Bergman; M Morgan
Journal:  J Clin Hypertens       Date:  1985-12       Impact factor: 3.738

10.  Total effective compliance, cardiac output and fluid volumes in essential hypertension.

Authors:  G M London; M E Safar; A C Simon; J M Alexandre; J A Levenson; Y A Weiss
Journal:  Circulation       Date:  1978-05       Impact factor: 29.690

View more
  1 in total

Review 1.  Heterogeneity of response of peripheral arteries to antihypertensive drugs in essential hypertension. Basic effects and functional consequences.

Authors:  J Levenson; A Simon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.